The proposed research is intended to determine if supplementation of relatively high dose
vitamin D in chronic urticaria patients receiving omalizumab will result in continued
symptomatic control of hives after the discontinuation of omalizumab.
The purpose of this study is to learn how much DHA to give to mothers in order to provide
enough to the baby. Researchers will also learn if there are differences in development of
the baby up to 12 months after birth.